Smartee Launches World's First Sleep Aligner Combining Anti-Snoring Therapy with Teeth Alignment

SHANGHAI, Oct. 13, 2025 /PRNewswire/ -- Smartee Denti-Technology today announced the global launch of the Smartee Sleep Aligners, a clear aligner device designed to help manage obstructive sleep apnoea hypopnoea syndrome (OSAHS) and primary snoring (PS). The new series includes two versions: Smartee SA, which focuses on the treatment of OSAHS and PS, and Smartee SA Plus. The latter can treat OSAHS while simultaneously addressing orthodontic issues. Together, they provide clinicians with an invisible alternative to conventional OSAHS treatment therapies, offering greater comfort and compliance, and improving sleep quality.

Addressing a global health challenge

OSAHS is one of the most prevalent sleep-related breathing disorders. Early signs often include habitual snoring caused by airway narrowing. As the condition progresses, patients may experience repeated breathing interruptions during sleep, which not only impair rest quality but are also linked to serious cardiovascular and metabolic risks.

The Smartee Sleep Aligners Series addresses this challenge through digitally customized clear aligners with a dual-splint locking system that advances the mandible while distributing occlusal forces to stabilize the jaw. This mandibular repositioning increases the volume of the velopharyngeal and oropharyngeal airways, improving airflow and alleviating OSAHS symptoms. Additionally, the appliance helps to reposition the mandible, which also leads to improved tongue base positioning, contributing to an expanded pharyngeal airway and reduced obstruction.

This device is made from a 1 mm-thick dental sheet, which offers enhanced comfort with minimal foreign body sensation. It demonstrates better patient acceptability and wear compliance.

There are two treatment options for OSAHS.

1. Smartee SA

• Indications: Simple snoring (without apnea), mild-to-moderate OSAHS, patients intolerant to CPAP, or those unsuitable for surgery.
• Function: Enlarge the velopharyngeal and oropharyngeal airway volume via mandibular advancement.
• Benefit: Titration assists clinicians in efficiently identifying the optimal mandibular advancement setting.

2. Smartee SA Plus

• Indications: Mild-to-moderate OSAHS combined with mild anterior misalignment.
• Function:
  Daytime: Correcting anterior teeth with regular clear aligners.
  Nighttime: Maintains airway patency and reduces snoring by wearing specially designed aligners with the mandibular advancement feature.
• Benefit: Offers both integrated daytime orthodontic correction and nocturnal snore suppression.

Global Availability

Both appliances are now available for clinicians to order directly through the Smartee Case Management System. By combining digital orthodontics with airway management, the Smartee SA and SA Plus series underscores Smartee's commitment to delivering innovative, clinically proven, and patient-centric solutions for doctors and patients worldwide.

For more information about the Smartee Sleep Aligners, please visit: Smartee LinkedIn Newsletter

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Smartee Launches World's First Sleep Aligner Combining Anti-Snoring Therapy with Teeth Alignment

SINGAPORE, Dec. 8, 2025 /PRNewswire/ -- AI/ML health-tech startup Respiree has received approval from the Health Sciences Authority (HSA) for its 1Bio™AI-Acute toolbox as a Class B software-as-a-medical device (SaMD). The solution is designed to support healthcare professionals in identifying acute inpatient deterioration using AI-enabled machine learning models. Compared to the current standard of care, 1Bio™AI-Acute delivers significantly higher precision in acute deterioration notifications, resulting in fewer false alerts and more efficient clinical support.

The 1Bio™AI-Acute system uses only bedside-recorded vital signs—pulse rate, respiratory rate, oxygen saturation, and systolic blood pressure—to generate a probability score that assists clinicians in determining whether additional monitoring may be required. This score provides an indication of the patient's general physiological state: the higher the score, the greater the likelihood that the patient may require additional monitoring due to potential acute deterioration.

WHY IT MATTERS

"Current early-warning scores that rely on threshold-based methods often suffer from low precision, leading to a high number of alarms and notifications. Advanced AI-driven machine learning models have the potential to deliver significantly greater precision, reducing unnecessary alerts/notifications, thus enabling healthcare professionals to better focus their time on delivering quality patient care," said Dr. Gurpreet Singh, CEO and Founder of Respiree.

The 1Bio™AI-Acute is readily available to healthcare professionals through Respiree's 1Bio™ platform, which recently received regulatory clearance together with the RS001 wearable device. With this milestone, the 1Bio™AI-Acute toolbox, the 1Bio™platform, and the RS001 wearable are all now approved by HSA.

With the HSA approval for the 1Bio™AI-Acute toolbox, Respiree is now setting its sights on expanding the 1Bio™AI-Acute regulatory approvals across other APAC and ANZ regions, as well as in the United States, in the coming months.

HSA's approval of the 1Bio™AI-Acute toolbox follows the validation study that was recently peer-reviewed and published in the Mayo Clinic Proceedings.

About Respiree

Respiree™ is an AI/ML health tech company building clinically-validated AI for managing disease progression. Respiree™ products are CE marked and has received regulatory clearances from the Therapeutic Goods Administration and the United States Food and Drug Administration (FDA).

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION